84478-75-1

Basic information

• Product Name: 2-Chloro-4-fluoro-5-nitrophenol
• Synonyms: 2-Chloro-4-fluoro-5-nitropheno;4-Chloro-2-fluoro-5-hydroxynitrobenzene;2-CHLORO-4-FLUORO-5-NITROBENZENOL;2-CHLORO-4-FLUORO-5-NITROPHENOL
• CAS NO: 84478-75-1
• Molecular Formula: C₆H₃ClFNO₃
• Molecular Weight: 191.54
• EINECS: 1533716-785-6
• Product Categories: Phenyls & Phenyl-Het;Phenol&Thiophenol&Mercaptan;API intermediates;Phenyls & Phenyl-Het
• Mol File: 84478-75-1.mol
• Article Data: 14

Chemical Properties

• Melting Point: 105-108°C
• Boiling Point: 298.7 °C at 760 mmHg
• Flash Point: 134.5 °C
• Appearance: /
• Density: 1.653 g/cm³
• Vapor Pressure: 0.000703mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: soluble in Methanol
• PKA: 6.58±0.24(Predicted)
• CAS DataBase Reference: 2-Chloro-4-fluoro-5-nitrophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-fluoro-5-nitrophenol(84478-75-1)
• EPA Substance Registry System: 2-Chloro-4-fluoro-5-nitrophenol(84478-75-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 84478-75-1(Hazardous Substances Data)

Usage

General Description

2-Chloro-4-fluoro-5-nitrophenol, also known as CNFP, is a chemical compound with the molecular formula C6H3ClFNO3. It is a yellow solid with a strong odor, and it is commonly used as a precursor in the synthesis of various pharmaceuticals and agrochemicals. CNFP is also known for its antibacterial and antifungal properties, making it a useful ingredient in various antimicrobial products. Additionally, it is used as an intermediate in the manufacturing of dyes, pigments, and plasticizers. However, CNFP is considered to be toxic and harmful if ingested, inhaled, or in contact with skin, and appropriate safety measures should be taken when handling this chemical.

InChI:InChI=1/C6H3ClFNO3/c7-3-1-4(8)5(9(11)12)2-6(3)10/h1-2,10H

Upstream product

• 153406-19-0 (2-chloro-4-fluorophenyl) ethyl carbonate 
• 1996-41-4 2-chloro-4-fluorophenol 
• 153471-75-1 (2-chloro-4-fluoro-5-nitrophenyl) ethyl carbonate 
• 84478-88-6 2-chloro-4-fluoro-methoxycarbonyloxybenzene 
• 84478-89-7 2-chloro-4-fluoro-5-nitro-methoxycarbonyloxybenzene 

Downstream Products

• 844678-33-7 1-chloro-2-cyclohexylmethoxy-5-fluoro-4-nitrobenzene 
• 344612-73-3 methyl 2-(2-chloro-4-fluoro-5-nitrophenoxy)propionate 
• 134814-96-3 2-chloro-4-fluoro-5-nitrophenol methoxymethyl ether 
• 84478-63-7 4-chloro-2-fluoro-5-isopropoxy-nitrobenzene 
• 1020173-36-7 5-(4-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)pyrimidin-2-yloxy)-2-fluorobenzenamine 
• 1020173-37-8 5-(4-(1H-pyrazol-4-yl)pyrimidin-2-yloxy)-2-fluorobenzenamine 
• 1020172-86-4 2-fluoro-5-(pyridine-3-yloxy)aniline 
• 1020173-92-5 4-(3-amino-4-fluorophenoxy)-N-methylpyrimidin-2-amine trifluoroacetate 
• 1020172-28-4 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-5-(2-(methylamino)pyrimidin-4-yloxy)phenyl)urea 
• 1020172-92-2 5-(5-chloropyridin-3-yloxy)-2-fluoroaniline 
• 1020173-02-7 5-(3-amino-4-fluorophenoxy)picolinonitrile 
• 1020172-94-4 5-(3-amino-4-fluorophenoxy)picolinic acid 
• 1020172-95-5 (5-(3-amino-4-fluorophenoxy)pyridin-2-yl)methanol 
• 1020172-96-6 2-fluoro-5-(6-methylpyridin-3-yloxy)benzenamine 

Relevant articles and documents

Development of a scalable synthesis of a vascular endothelial growth factor receptor-2 kinase inhibitor: Efficient construction of a 6-etherified [1,2,4]triazolo[1,5-a]pyridine-2-amine Core

A practical and scalable synthesis of the vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibitor 1 has been developed. The key features of the process development include facile preparation of the key raw material 3-amino-4- fluorophenol, chemoselective nucleophilic aromatic substitution of 5-chloro-2-nitropyridine with phenol, a safe one-pot synthesis of a substituted urea using an isothiocyanate generated in situ from inexpensive materials, and improvement of the yield of acylation in the end game. The optimized six-step synthesis afforded 1·H2O in 54% overall yield, twice as much as the yield of the original synthesis, without chromatographic purification. In addition, a robust recrystallization procedure to afford the desired crystal form of 1 was also developed.

CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES

The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.